It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.
Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.
An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).
John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?
FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma.
Will they be successful despite the huge complexity involved in the underlying processes?
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
Part 1 of an interview with Prof Waseem Qasim.
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
A look at the new CLL 17p deletion data at ASH in the late breaker session
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.
An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
What to make of the various combination trials presented at ASCO 2016?
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours
Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.
Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer
Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.
Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Can biomarkers help us improve clinical trial outcomes?
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
#LeonardList showcases 10 Lymphoma Abstracts at ASH16
Tackling heterogeneity in older people with AML using novel targeted therapies.
A look at the latest data for a CD79b targeted ADC in lymphomas
How are recently approved novel therapies impacting the CLL landscape and where are we going next?
A look at some promising agents in new product development emerging in early CLL trials
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.
Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?
How crowdsourcing data from breast cancer patients may help future clinical R&D
2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...
A draft manifesto for IO in cancer research and what we need to learn
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.
Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?
A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.
Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
Interview with Professor Peter Schmid, Barts Cancer Institute.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Encouraging new developments in GBM with a novel CAR T cell therapy
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts